Core Viewpoint - STRATA Skin Sciences, Inc. has filed a Form 25 with the SEC to deregister its common stock and has suspended trading on Nasdaq, indicating a strategic shift to "go dark" and reduce compliance costs [1][2]. Group 1: Company Actions - The company plans to file a Form 15 around March 2, 2026, to terminate the registration of its common stock and suspend reporting obligations under the Exchange Act [1]. - The delisting from Nasdaq is expected to save significant time and money in general and administrative expenses, allowing the company to focus on its operating plan and customer needs [2]. Group 2: Financial Position - STRATA finished the 2025 fiscal year with a strong balance sheet, including $8 million in cash, indicating financial stability [3]. - The company is engaging with its lender to adjust loan terms to reflect its new status as a private company, with management confident in a favorable outcome [3]. Group 3: Strategic Focus - The decision to "go dark" is aimed at minimizing management distractions related to compliance, allowing for a greater focus on long-term value creation and market expansion [2][3]. - The company anticipates leveraging changes in CPT codes to enhance its market position for XTRAC® excimer laser and TheraclearX® users, which could drive future growth [3].